Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential

被引：16

作者：

Baldini, Capucine ^{[1
]}

Champiat, Stephane ^{[1
]}

Vuagnat, Perrine ^{[1
]}

Massard, Christophe ^{[1
]}

机构：

[1] Univ Paris Saclay, Drug Dev Dept, Gustave Roussy Canc Campus, Villejuif, France

来源：

ONCOTARGETS AND THERAPY | 2019年 / 12卷

关键词：

immunotherapy; PD-L1; inhibitor; durvalumab; urothelial carcinoma; bladder cancer; IMMUNE CHECKPOINT INHIBITOR; PHASE-I TRIALS; PROSPECTIVE VALIDATION; PROGNOSTIC SCORE; BLADDER-CANCER; CELL CARCINOMA; IMMUNOTHERAPY; CHEMOTHERAPY; MULTICENTER; CISPLATIN;

D O I：

10.2147/OTT.S141040

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has been given breakthrough in UC in 2017 in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression,12 months after neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Food and Drug Administration approval was given on the results of the Phase I/II study of MEDI 4736. In this article, we will review available data on durvalumab in the treatment of locally advanced and metastatic UC and discuss therapeutic potential.

引用

页码：2505 / 2512

页数：8

共 46 条

[1] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[2]

[Anonymous], DURV IMF

[3] Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends [J].

Antoni, Sebastien ;

Ferlay, Jacques ;

Soerjomataram, Isabelle ;

Znaor, Ariana ;

Jemal, Ahmedin ;

Bray, Freddie .

EUROPEAN UROLOGY, 2017, 71 (01) :96-108

[4] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study [J].

Apolo, Andrea B. ;

Infante, Jeffrey R. ;

Balmanoukian, Ani ;

Patel, Manish R. ;

Wang, Ding ;

Kelly, Karen ;

Mega, Anthony E. ;

Britten, Carolyn D. ;

Ravaud, Alain ;

Mita, Alain C. ;

Safran, Howard ;

Stinchcombe, Thomas E. ;

Srdanov, Marko ;

Gelb, Arnold B. ;

Schlichting, Michael ;

Chin, Kevin ;

Gulley, James L. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2117-+

[5] Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials [J].

Arkenau, Hendrik-Tobias ;

Barriuso, Jorge ;

Olmos, David ;

Ang, Joo Ern ;

de Bono, Johann ;

Judson, Ian ;

Kaye, Stan .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2692-2696

[6] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[7] Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score) [J].

Bigot, Frederic ;

Castanon, Eduardo ;

Baldini, Capucine ;

Hollebecque, Antoine ;

Calmona, Alberto ;

Postel-Vinay, Sophie ;

Angevin, Eric ;

Armand, Jean-Pierre ;

Ribrag, Vincent ;

Aspeslagh, Sandrine ;

Varga, Andrea ;

Bahleda, Rastislav ;

Menis, Jessica ;

Gazzah, Anas ;

Michot, Jean-Marie ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Massard, Christophe .

EUROPEAN JOURNAL OF CANCER, 2017, 84 :212-218

[8] Hyperprogressive disease: recognizing a novel pattern to improve patient management [J].

Champiat, Stephane ;

Ferrara, Roberto ;

Massard, Christophe ;

Besse, Benjamin ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :748-762

[9] Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 [J].

Champiat, Stephane ;

Dercle, Laurent ;

Ammari, Samy ;

Massard, Christophe ;

Hollebecque, Antoine ;

Postel-Vinay, Sophie ;

Chaput, Nathalie ;

Eggermont, Alexander ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

CLINICAL CANCER RESEARCH, 2017, 23 (08) :1920-1928

[10] Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder [J].

Dash, Atreya ;

Galsky, Matthew D. ;

Vickers, Andrew J. ;

Serio, Angel M. ;

Koppie, Theresa M. ;

Dalbagni, Guido ;

Bochner, Bernard H. .

CANCER, 2006, 107 (03) :506-513

← 1 2 3 4 5 →